{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T07:24:39Z","timestamp":1782631479937,"version":"3.54.5"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Guangdong Basic and Applied Basic Research Fund","award":["2023A1515220093"],"award-info":[{"award-number":["2023A1515220093"]}]},{"name":"Guangdong Provincial Medical Research Fund","award":["B2022065"],"award-info":[{"award-number":["B2022065"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>In order to explore efficient ATP-competitive mTOR inhibitors and aid the development of targeted anticancer drugs, this study focuses on virtual screening and molecular dynamics simulations. The compounds were sourced from the ChemDiv commercial compound library, and through virtual screening, 50 ligands with favorable binding modes and excellent docking scores were selected from 902,998 compounds. Molecular dynamics simulations, including RMSD (Root Mean Square Deviation) and RMSF (Root Mean Square Fluctuation), were used to further evaluate these 50 ligands. Structural stability, key residue interactions, hydrogen bonding, binding free energy, and other factors were quantitatively and qualitatively analyzed. Top1, top2, and top6, which exhibited outstanding performance, were identified. Simulations revealed that they bind stably in the active region of the mTOR protein, forming hydrogen bonds, \u03c0-\u03c0 interactions, and hydrophobic interactions with key amino acid residues such as VAL-2240 and TRP-2239. This study provides a solid theoretical foundation for the development of mTOR inhibitors. Subsequent efforts will focus on optimizing these compounds, targeting structural adjustments to enhance their biological activity and specificity towards mTOR, thereby achieving more precise targeting and treatment of tumors.<\/jats:p>","DOI":"10.1371\/journal.pone.0319608","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T17:46:30Z","timestamp":1746467190000},"page":"e0319608","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Virtual screening and molecular dynamics simulation study of ATP-competitive inhibitors targeting mTOR protein"],"prefix":"10.1371","volume":"20","author":[{"given":"Mei-Yu","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-8335","authenticated-orcid":true,"given":"Hui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"pone.0319608.ref001","doi-asserted-by":"crossref","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway?","volume":"12","author":"Y Peng","year":"2022","journal-title":"Front Oncol"},{"key":"pone.0319608.ref002","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"L Yu","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"pone.0319608.ref003","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.3390\/ijms24054522","article-title":"Drugging the PI3K\/AKT\/mTOR pathway in ER+ breast cancer","volume":"24","author":"CL Alves","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"pone.0319608.ref004","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11684-020-0812-7","article-title":"mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?","volume":"15","author":"S-Y Sun","year":"2021","journal-title":"Front Med"},{"issue":"5","key":"pone.0319608.ref005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3390\/cells8050431","article-title":"mTOR signaling pathway in cancer targets photodynamic therapy in vitro","volume":"8","author":"SM Ayuk","year":"2019","journal-title":"Cells"},{"issue":"11","key":"pone.0319608.ref006","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.3390\/ijms25116141","article-title":"mTOR: its critical role in metabolic diseases, cancer, and the aging process","volume":"25","author":"SK Marafie","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"10","key":"pone.0319608.ref007","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.molmed.2007.08.001","article-title":"Targeting the mTOR signaling network in cancer","volume":"13","author":"GG Chiang","year":"2007","journal-title":"Trends Mol Med"},{"issue":"8","key":"pone.0319608.ref008","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molmed.2005.06.007","article-title":"An expanding role for mTOR in cancer","volume":"11","author":"DA Guertin","year":"2005","journal-title":"Trends Mol Med"},{"issue":"1","key":"pone.0319608.ref009","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"DA Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"pone.0319608.ref010","first-page":"21","article-title":"Sirolimus, the first mTOR inhibitor","volume":"26 Suppl 2","author":"JA S\u00e1nchez-Plumed","year":"2006","journal-title":"Nefrologia"},{"issue":"1","key":"pone.0319608.ref011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-9966-28-3","article-title":"Effect of sirolimus on urinary bladder cancer T24 cell line","volume":"28","author":"R Pinto-Leite","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"issue":"3 Suppl","key":"pone.0319608.ref012","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: its discovery, biological properties, and mechanism of action","volume":"35","author":"SN Sehgal","year":"2003","journal-title":"Transplant Proc"},{"issue":"6","key":"pone.0319608.ref013","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/MOH.0b013e32833e5b2e","article-title":"Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update","volume":"17","author":"C Cutler","year":"2010","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"pone.0319608.ref014","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1091\/mbc.5.1.105","article-title":"TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast","volume":"5","author":"SB Helliwell","year":"1994","journal-title":"Mol Biol Cell"},{"issue":"3","key":"pone.0319608.ref015","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","article-title":"Regulation and metabolic functions of mTORC1 and mTORC2","volume":"101","author":"A Szwed","year":"2021","journal-title":"Physiol Rev"},{"issue":"1","key":"pone.0319608.ref016","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12964-022-00859-7","article-title":"mTORC2: a multifaceted regulator of autophagy","volume":"21","author":"Y Sun","year":"2023","journal-title":"Cell Commun Signal"},{"issue":"169","key":"pone.0319608.ref017","doi-asserted-by":"crossref","first-page":"230100","DOI":"10.1183\/16000617.0100-2023","article-title":"Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis","volume":"32","author":"JF Evans","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"1","key":"pone.0319608.ref018","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13058-020-01271-0","article-title":"Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K\/AKT\/mTORC1 pathway with different clinical implications","volume":"22","author":"C Vernieri","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"7448","key":"pone.0319608.ref019","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12122","article-title":"mTOR kinase structure, mechanism and regulation","volume":"497","author":"H Yang","year":"2013","journal-title":"Nature"},{"issue":"3","key":"pone.0319608.ref020","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/ph14030282","article-title":"Marine-derived natural products as ATP-competitive mTOR kinase inhibitors for cancer therapeutics","volume":"14","author":"S Parate","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"pone.0319608.ref021","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejmech.2017.02.015","article-title":"Design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine derivatives as mTOR inhibitors","volume":"129","author":"B Mao","year":"2017","journal-title":"Eur J Med Chem"},{"issue":"10","key":"pone.0319608.ref022","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2174\/1567201818666210609161301","article-title":"Targeted drug delivery: trends and perspectives","volume":"18","author":"S Ashique","year":"2021","journal-title":"Curr Drug Deliv"},{"issue":"7\u20138","key":"pone.0319608.ref023","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/1061186X.2020.1744157","article-title":"Therapeutic drugs and drug delivery systems targeting stromal cells for cancer therapy: a review","volume":"28","author":"Z Li","year":"2020","journal-title":"J Drug Target"},{"issue":"12","key":"pone.0319608.ref024","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.drudis.2016.08.002","article-title":"Recent advances in cancer drug discovery targeting RAS","volume":"21","author":"CY Wilson","year":"2016","journal-title":"Drug Discov Today"},{"issue":"1","key":"pone.0319608.ref025","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1038\/s41467-022-32486-8","article-title":"A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy","volume":"13","author":"BD Ross","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"pone.0319608.ref026","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/acs.jctc.7b00028","article-title":"How molecular size impacts RMSD applications in molecular dynamics simulations","volume":"13","author":"K Sargsyan","year":"2017","journal-title":"J Chem Theory Comput"},{"issue":"1","key":"pone.0319608.ref027","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12896-021-00697-4","article-title":"Insights from molecular docking and molecular dynamics on the potential of vitexin as an antagonist candidate against lipopolysaccharide (LPS) for microglial activation in neuroinflammation","volume":"21","author":"MAF Yahaya","year":"2021","journal-title":"BMC Biotechnol"},{"issue":"6","key":"pone.0319608.ref028","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1021\/acs.jcim.4c00054","article-title":"HBCalculator: A Tool for Hydrogen Bond Distribution Calculations in Molecular Dynamics Simulations","volume":"64","author":"Y Wang","year":"2024","journal-title":"J Chem Inf Model"},{"issue":"15","key":"pone.0319608.ref029","doi-asserted-by":"crossref","first-page":"154902","DOI":"10.1063\/1.4824769","article-title":"High-functionality star-branched macromolecules: polymer size and virial coefficients","volume":"139","author":"F Randisi","year":"2013","journal-title":"J Chem Phys"},{"issue":"3","key":"pone.0319608.ref030","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1021\/acsmedchemlett.2c00541","article-title":"Recent Advances in Alchemical Binding Free Energy Calculations for Drug Discovery","volume":"14","author":"I Muegge","year":"2023","journal-title":"ACS Med Chem Lett"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0319608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T17:46:37Z","timestamp":1746467197000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0319608"}},"subtitle":[],"editor":[{"given":"Mohd","family":"Rehan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0319608","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]}}}